Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders

Area of Science:

• Biochemistry
• Genetics
• Cell Biology

Background:

• Lysosomal storage disorders (LSDs) are inherited metabolic diseases affecting ~1 in 5000–7000 births.
• Caused by enzyme/transporter deficiencies in lysosomes, leading to substrate accumulation and multi-organ pathologies.
• Defects in membrane trafficking and lipid homeostasis also contribute to LSD pathogenesis.

Purpose of the Study:

• To review four distinct LSDs: Niemann-Pick type C, Fabry, Gaucher, and Pompe disease.
• To emphasize the role of membrane trafficking defects in LSD pathology.
• To summarize current therapeutic strategies for LSDs.

Main Methods:

• Literature review focusing on Niemann-Pick type C, Fabry, Gaucher, and Pompe diseases.
• Analysis of genetic mutations, enzyme deficiencies, and cellular mechanisms.
• Examination of current and emerging therapeutic approaches.

Main Results:

• Niemann-Pick type C involves cholesterol export defects, while Fabry, Gaucher, and Pompe diseases stem from hydrolase deficiencies.
• Mutations affecting lysosomal protein trafficking and lipid homeostasis are implicated in disease pathology.
• Substrate reduction therapy and pharmacological chaperone therapy are key treatment strategies.

Conclusions:

• LSDs are a diverse group of genetic disorders with significant clinical impact.
• Membrane trafficking defects play a crucial role in the pathogenesis of various LSDs.
• Targeted therapies, including substrate reduction and chaperone therapy, offer promising treatment avenues.